Logo

Press Releases

8/2/2019
FDA Approves Daiichi Sankyo’s TURALIO™ (pexidartinib) for the Treatment of Select Patients with TGCT, a Rare and Debilitating Tumor

7/29/2015
Daiichi Sankyo and Plexxikon Announce Study Published in NEJM Demonstrates PLX3397 Induced Prolonged Tumor Regression in Tenosynovial Giant Cell Tumor (TGCT) in Most Patients

5/7/2015
Plexxikon and Merck to Collaborate on Combination Study Evaluating Investigational Immuno-oncology Regimen

12/11/2014
Plexxikon and QuantumLeap Healthcare Collaborative Announce Selection of PLX3397 for I-SPY 2 TRIAL in Breast Cancer

More News 

PR Contact

Susan Kinkead
Kinkead Communications
415.509.3610
susan@kinkeadcomm.com

Press Kit

Plexxikon’s corporate materials, including corporate logo, executive bios and photos.

Press Kit page

  • About Us
    • About Us
    • Leadership
  • Science
    • Publications
  • Pipeline
    • Development Pipeline
    • Preclinical Pipeline
    • Expanded Access
  • Partnering
  • News
    • Press Releases
    • PR Contacts
    • Press Kit
  • Careers
    • Join our Team
    • Values
    • Job Opportunities
      • Scientist, Clinical and Translational
    • Benefits
  • Contact Us
    • Directions
  • Home
  • About Us
    • About Us
    • Leadership
  • Science
    • Publications
  • Pipeline
    • Development Pipeline
    • Preclinical Pipeline
    • Expanded Access
  • Partnering
  • News
    • Press Releases
    • PR Contacts
    • Press Kit
  • Careers
    • Join our Team
    • Values
    • Job Opportunities
      • Scientist, Clinical and Translational
    • Benefits
  • Contact Us
    • Directions
logo
© 2021 Plexxikon All rights reservedWebsite Design: Hane Chow, Inc.